BioSpace News Archive

OKYO Pharma Limited is pleased to announce its final audited results for the year ended 31 March 2021.

Centene Corporation (NYSE: CNC) announced today its North Carolina subsidiary, Carolina Complete Health – a provider-led health plan established in partnership with the North Carolina Medical Society and working in conjunction with the North Carolina Community Health Center Association – will help coordinate integrated physical health.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 74,600 shares of Karyopharm’s common stock to 11 newly-hired employees, with a grant date of July 30, 2021.

Exo (pronounced “echo”), a pioneering health information and devices company, closed a $220 million Series C investment round.

4D pharma plc, a pharmaceutical company leading the development of Live Biotherapeutic products, a novel class of drug derived from the microbiome, announces two poster presentations at the European Society for Medical Oncology Congress, held from September 16-21, 2021.

Castle Biosciences, Inc. announced its continued collaboration with the Melanoma Research Foundation, a non-profit organization leading the melanoma community to transform melanoma from one of the deadliest cancers to one of the most treatable through research, education and advocacy.

Company appoints six new members to SAB to maximize the company’s impact in the proteomics domain

SaNOtize Research and Development Corp. and Glenmark Pharmaceuticalsannounced an exclusive long-term strategic partnership to manufacture, market and distribute SaNOtize’s breakthrough Nitric Oxide Nasal Spray for COVID-19 treatment, in India and other Asian markets including Singapore, Malaysia Hong Kong, Taiwan, Nepal, Brunei, Cambodia, Laos, Myanmar, Sri Lanka, Timor-Leste and Vietnam.

Taysha Gene Therapies, Inc. announced its participation in a fireside chat for the BTIG Virtual Biotechnology Conference and a panel for the 2021 Wedbush Pacgrow Healthcare Virtual Conference.

Biogen Inc. today announced results from the two-year prospective, randomized, interventional, controlled, open-label Phase 3b NOVA study (NCT03689972).